Comparative efficacy of zanubrutinib (ZANU) versus fixed-duration acalabrutinib plus venetoclax (AV) for first-line treatment of chronic lymphocytic leukemia (CLL): A matching-adjusted indirect comparison (MAIC)

No Thumbnail Available

All Authors

Munir,Tahla
Yang,Keri
Xu,Sheng
Williams,Rhys
Shadman,Mazyar

LTHT Author

Munir, Talha

LTHT Department

Oncology
Haematology

Non Medic

Publication Date

2025

Item Type

Article

Language

Subject

Subject Headings